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In  the present  study,  we  evaluated  the  in  vitro  antiprotozoal  activity  of  a guaianolide  (11,13-
dehydrocompressanolide)  isolated  from  Tanacetum  parthenium  against  Trypanosoma  cruzi  and
investigated  the  possible  combinational  effect  of  guaianolide  and  benznidazole.  The  isolated  compound
was  shown  to  be effective  against  T. cruzi,  with  IC50 values  of 18.1  ± 0.8  and  66.6 ±  1.3 M  against
the  multiplicative  epimastigote  and  amastigote  forms,  respectively.  The  best results  were obtained
against  trypomastigotes,  with  an  EC50 of  5.7 ± 0.7  M.  The  guaianolide  presented  no toxicity  in LLCMK2
cells  (CC50 of 93.5 M)  and  was 16.4-fold  more  selective  for  trypomastigotes.  The  study  of  the  com-
binational  effect  of  benznidazole  and  guaianolide  revealed  the  presence  of  a synergistic  effect  against
the  epimastigote  form  and  marginal  additive  effect  against  the  trypomastigote  form.  Striking  mor-
phological  changes  were  observed  in  epimastigotes  treated  with  guaianolide,  such  as  thinning  and
stretching  of  the  cell  body  and  ﬂagellum  and  changes  in  the  format  of the  cell body  with  apparent  leak-
age  of the  cytoplasmic  content  in  trypomastigote  forms.  The  ultrastructural  analysis  of  epimastigotes
revealed  the presence  of  membranes  that  involved  organelles  and  formation  of  myelin-like  ﬁgures.  Flow
cytometry  revealed  a cell  volume  reduction  and  decrease  in  mitochondrial  membrane  potential.  How-
ever, no  major  changes  in  cell  membrane  integrity  were  found  in  the  epimastigote  form  treated  with
guaianolide.
© 2012 Elsevier GmbH. Open access under the Elsevier OA license. ntroduction
Chagas’ disease is considered a major public health problem in
he Americas. Presently, 10 million people are infected worldwide,
ith over 25 million at risk for infection, mostly in Latin America.
his disease kills more than 10,000 people each year. Recently, new
odes of transmission, including oral, have caused alarm in several
ountries, including Brazil, Colombia, and Venezuela (WHO  2010;
ereira et al. 2010).
The currently available treatment of infected patients is limited
ecause the only drugs available, nifurtimox (Lampit) and ben-
nidazole (Radanil, Rochagan), have limited efﬁcacy and present
ystemic toxicity that causes several side effects (Maya et al. 2007;
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vnakamura@gmail.com (C.V. Nakamura).
944-7113     © 2012 Elsevier GmbH.  
ttp://dx.doi.org/10.1016/j.phymed.2012.09.011
Open access under the Elsevier OA license. Soeiro et al. 2009). Therefore, the development of new effective and
safe drugs is urgently needed for the treatment of Chagas’ disease.
Sesquiterpene lactones are a large group of molecules with
several biological activities and uses for humans, including antiin-
ﬂammatory, anticancer, antimicrobial, and antiprotozoal (Tiuman
et al. 2005; Izumi et al. 2008; Ghantous et al. 2010; Chaturvedi
2011; Julianti et al. 2011). These different activities have been
linked mainly to -methylene--lactone functionality, which can
react with biological nucleophiles, such as sulfhydryl groups,
through Michael-type addition. They can inhibit various thiol-
containing enzymes involved in the synthesis and processing of
proteins, RNA, and DNA (Kupchan et al. 1970; Picman 1986; Arantes
et al. 2009).
These features make sesquiterpene lactones potent molecules
for the treatment of human pathogenic protozoa species, includ-
ing trypanosomatids. Among the bioactive sesquiterpenes, the
guaianolide 11,13-dehydrocompressanolide recently isolated from
Tanacetum parthenium deserves attention because of its activity
against Leishmania amazonensis and low toxicity (Silva et al. 2010).
Thus, the purpose of the present study was  to evaluate the in
vitro trypanocidal activity of guaianolide isolated from the aerial
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(guaianolide and benznidazole) were added alone or in combina-ig. 1. Chemical structure of guaianolide 11,13-dehydrocompressanolide isolated
rom Tanacetum parthenium (A) and benznidazole (B).
arts of T. parthenium against T. cruzi and investigate the possible
ombinational effect of guaianolide and benznidazole.
aterials and methods
solation of guaianolide
The powder of the aerial parts of T. parthenium was kindly pro-
ided by the Laboratório Botânico Flores & Ervas (lot no. 029086;
iracicaba, São Paulo, Brazil). The general procedure for the isola-
ion of guaianolide (11,13-dehydrocompressanolide; Fig. 1A) was
imilar to the procedure described for parthenolide (Tiuman et al.
005; Silva et al. 2010) with slight modiﬁcations. The compound
as characterized by mass spectra data (Micromass Quatro Micro;
PI Waters) and nuclear magnetic resonance (NMR) spectra data
Gemini 2000BB; Varian).
Stock solutions were prepared aseptically in dimethylsulfoxide
DMSO; Sigma, St. Louis, MO,  USA), with the ﬁnal concentration
f the experiments not exceeding 1%. Benznidazole (N-benzyl-
-nitro-1H-imidazole-1-acetamide; Fig. 1B), used as reference
rug, was purchased from Laboratório Central de Medicamentos,
ernambuco, Brazil.
arasites and cells
Epimastigote forms of T. cruzi (Y strain) were maintained at 28 ◦C
y weekly transfers in liver infusion tryptose medium (LIT) sup-
lemented with 10% inactivated fetal bovine serum (FBS; Gibco
nvitrogen, New York, USA).
LLCMK2 cells (epithelial cells from the kidney of the monkey
acaca mulatta) were maintained in Dulbecco’s modiﬁed Eagle’s
edium (DMEM; Gibco Invitrogen) supplemented with 2 mM l-
lutamine, 10% FBS, and 50 mg/l gentamicin at 37 ◦C in a humidiﬁed
% CO2 atmosphere.
Trypomastigote forms were obtained from the supernatant of a
onolayer of infected LLCMK2 cells in DMEM supplemented with
0% FBS at 37 ◦C in a humidiﬁed 5% CO2 atmosphere.
ntiproliferative activity of guaianolide on epimastigote forms
Epimastigote forms harvested during the exponential growth
hase were used for this assay. A cell density of 1.0 × 106 cells/ml
n LIT medium supplemented with 10% FBS was incubated in dupli-
ate at 28 ◦C for 96 h in 24-well microplates in the absence or
resence of increasing concentrations of guaianolide (1–50 M).
fterward, cell growth was estimated by counting the parasites
sing a Neubauer haemocytometer (Improved Double Neubauer),
nd IC50 and IC90 values (concentrations that inhibit cell growth
n 50% and 90%, respectively) were determined. The results are
xpressed as a percentage of growth inhibition compared with
ontrol cultures. Benznidazole was used as a reference drug.ne 20 (2012) 59– 66
Effect of guaianolide on the viability of trypomastigote forms
The tissue-culture-derived trypomastigote forms
(1.0 × 107 cells/ml) were resuspended in DMEM and added in
duplicate to 96-well microplates in the absence or presence of dif-
ferent concentrations of guaianolide (0.1–50 M).  Parasites were
incubated for 24 h at 37 ◦C in a 5% CO2 atmosphere. The results
were obtained by observing motility, allowing the determination
of the viability of the parasites, using the Pizzi–Brener method
(Brener 1962). The EC50 value (i.e., the concentration that lyses
50% of the parasites) was then calculated. Benznidazole was used
as a reference drug.
Activity of guaianolide on intracellular amastigote forms
To evaluate the effect on the intracellular amastigote forms,
a suspension of 2.5 ×105 LLCMK2 cells/ml in DMEM supple-
mented with 10% FBS was seeded in 24-well microplates that
contained round coverslips and then maintained at 37 ◦C in a
5% CO2 atmosphere for 24 h until a conﬂuent monolayer was
obtained. Trypomastigotes were added to the wells at a concen-
tration of 10 parasites per host cell. After 24 h, non-internalized
parasites were removed by washing, and the infected LLCMK2
cells were treated in duplicate with different concentrations of
guaianolide (50, 60, and 70 M)  for 96 h. The cells were ﬁxed
with methanol and stained with Giemsa, and the coverslips
were permanently prepared with Entellan (Merck). By count-
ing 200 cells under a light microscope (Olympus CX 31), we
estimated the percentage of infected cells and number of intra-
cellular amastigotes. The survival index (percentage of infected
cells × number of amastigotes per cell) and IC50 value were then
determined.
Cytotoxicity assay
LLCMK2 cells were assayed for the determination of cell via-
bility using a sulforhodamine B colorimetric assay. A suspension
of 2.5 × 105 cells was  seeded in a 96-well microplate and main-
tained at 37 ◦C in a 5% CO2 atmosphere for 24 h until a conﬂuent cell
monolayer was  obtained. Thereafter, the medium was removed,
and the cells were cultured with increasing concentrations of
guaianolide (37–500 M)  in triplicate for 96 h under the same con-
ditions as above. Control wells without treatment were included.
The cells were ﬁxed with 10% trichloroacetic acid for 1 h at 4 ◦C
and stained for 30 min  with 0.4% sulforhodamine B (SRB) in 1%
acetic acid. Bound SRB was dissolved with 10 mM  unbuffered Tris-
base (tris[hydroxymethyl]aminomethane) solution. Absorbance
was read in a 96-well plate reader (BIO-TEK FL-600 Microplate Flu-
orescence Reader) at 530 nm.  The results were calculated as the
ratio between the optical density of untreated and treated cells.
Dose–response curves were plotted, and CC50 values (50% cytotoxic
concentration) were estimated. The selectivity index (SI) was used
to compare cytotoxicity between LLCMK2 cells and trypomastig-
ote forms of T. cruzi (ratio: CC50 on LLCMK2 divided by EC50 of the
compound in the protozoa).
Evaluation of the combinatory effect between guaianolide and
benznidazole
Brieﬂy, epimastigote forms (1.0 × 106 cells/ml) in the exponen-
tial growth phase were resuspended in LIT medium supplemented
with 10% FBS. Afterward, different concentrations of the drugstion to the cell suspension in 24-well microplates. Cell growth was
determined by counting the parasites with a Neubauer haemocy-
tometer after 96 h. Trypomastigote forms (1.0 × 107 cells/ml) were
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Fig. 2. Effect of guaianolide (11,13-dehydrocompressanolide) in epimastigote forms. (A) Antiproliferative activity of guaianolide and benznidazole for 96 h at 28 ◦C. The
data  are expressed as mean ± SD of three independent experiments performed in duplicate. The results are expressed as a percentage of inhibition compared with control.
Morphological alterations were observed by SEM. (B) Untreated parasite that shows typical elongated morphology. (C and D) Parasites treated with IC50 and IC90, respectively,
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dor  96 h, showing thinning and stretching of the cell body and ﬂagellum. Ultrastr
lterations and organelles with normal morphology. (F–I) Parasites treated with IC50
ndicates membranes that envelope reservosomes and nucleus. Star indicates the fo
esuspended in DMEM and added to 96-well microplates that con-
ained different concentrations of the drugs alone or combined and
ncubated for 24 h at 37 ◦C. The results were obtained by observing
otility under a light microscope (Brener 1962). Cytotoxicity
as assessed by exposing the LLCMK2 cell monolayer to different
oncentrations of the drugs alone or combined for 96 h. Cell
rowth was assessed using the SRB colorimetric assay as described
bove. To evaluate the combinational effect of guaianolide and
enznidazole, we adopted the fractional inhibitory concentration
ndex (FICI) and used isobolograms. The FICI was  the sum of the
ractional inhibitory concentration (FIC) of drug A plus the FIC of
rug B. The FIC of drug A is the IC50 of the drug when it is used inl alterations were observed by TEM. (E) Untreated parasites, showing no plasma
aianolide for 96 h. k, kinetoplast; f, ﬂagellum; fp, ﬂagellar pocket; n, nucleus. Arrow
on of myelin-like ﬁgures. Scale bars = 1 m.
combination with drug B, divided by the IC50 of the drug when it
is used alone (Hallander et al. 1982).
Electron microscopy
Epimastigote and trypomastigote forms were treated as
described above with concentrations of guaianolide based on the
IC50 and IC90 values and then ﬁxed with 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer at 4 ◦C. For transmission electron
microscopy (TEM), the cells were postﬁxed in a solution that
contained 1% OsO4, 0.8% potassium ferrocyanide, and 10 mM CaCl2
in 0.1 M cacodylate buffer, dehydrated in an increasing acetone
6 edicine 20 (2012) 59– 66
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Table 1
Cell body size variation observed on epimastigote forms cultivated in the presence
of  guaianolide (11,13-dehydrocompressanolide).
Epimastigote Control IC50 (18.1 M)  IC90 (44.1 M)
M
Cell body
Length 8.04 ± 1.5 9.0 ± 2.3 10.5 ± 1.8
Width 1.89 ± 0.24 1.62 ± 0.12 1.33 ± 0.21
Flagellum
Length 8.15 ± 1.63 11.9 ± 1.7 13.7 ± 2.12 J. Cogo et al. / Phytom
radient, and embedded in Epon resin. Ultrathin sections were then
btained and observed on a Zeiss 900 TEM. For scanning electron
icroscopy (SEM), epimastigote and trypomastigote forms were
laced on a specimen support with poly-l-lysine. The samples
ere dehydrated in a graded series of ethanol, critical-point-dried
ith CO2, coated with gold, and observed on a Shimadzu SS-550
EM. The epimastigote forms were measured for the quantiﬁcation
f morphological changes.
low cytometry analysis
After the treatment described above with concentrations based
n the IC50 and IC90 values, epimastigote forms were washed,
nd the pellet was resuspended in phosphate-buffered saline
PBS). To evaluate the mitochondrial membrane potential (m),
he cells were incubated with 13.1 M rhodamine 123 (Rh123;
igma–Aldrich) for 15 min  at 37 ◦C. The carbonyl cyanide m-
hlorophenylhydrazone (100 M)  was used as a positive control.
o estimate plasma membrane integrity, the cells were incu-
ated with 3 M propidium iodide (PI; Invitrogen) for 5 min  at
7 ◦C. Antimycin (40 M)  and actinomycin D (50 M)  were used
s positive controls for plasma membrane integrity and cell vol-
me, respectively. Thereafter, the cell volume, m, and plasma
embrane integrity of individual cells were analyzed with a ﬂow
ytometer (FACSCalibur; Becton-Dickinson, Rutherford, NJ, USA).
ellQuest software (Joseph Trotter, The Scripps Research Institute,
a Jolla, CA, USA) was used for the data analyses. A total of 10,000
vents were acquired for each sample in the region previously
stablished as the one that corresponded to the parasites.
tatistical analyses and reproducibility of the results
All of the experiments were repeated at least three times
ndependently, and the data are expressed as mean ± standard
eviation. The statistical analysis was performed using Prism 4 soft-
are (GraphPad Software, San Diego, CA, USA). Student’s t-test or
ne-way analysis of variance (ANOVA) followed by Tukey’s or Dun-
ett’s tests was used. Values of p < 0.05 were considered statistically
igniﬁcant.
esults
We initially evaluated the activity of guaianolide in epimastig-
te forms. This compound caused a dose-dependent progressive
nhibition of protozoa growth, exhibiting an IC50 of 18.1 ± 0.8 M
nd IC90 of 44.1 ± 0.7 M (Fig. 2A). The IC50 of the reference drug
enznidazole was 8.1 ± 0.3 M.
To investigate and identify the organelles that might be the
otential targets of guaianolide on T. cruzi, SEM, TEM, and
ow cytometry techniques were employed. Scanning electron
icroscopy was used to further investigate morphological alter-
tions in the protozoa treated with guaianolide (Fig. 2C and D).
pimastigotes treated with the IC50 concentration of guaianolide
howed an increase of approximately 11.9% in cell length and
ecrease of approximately 14.3% in cell body width (Table 1). These
hanges were observed in greater proportions when the cells were
reated with the IC90 concentration of 44.1 M,  with an increase of
pproximately 30.6% in cell length and decrease of approximately
0% in cell body width compared with untreated cells (Fig. 2B). The
iggest change was observed in the ﬂagellum, with an increase of
pproximately 46% and 68% in cells treated with 18.1 and 44.1 M,
espectively.To conﬁrm the volume reduction observed by SEM, epimastig-
tes treated with 18.1 and 44.1 M guaianolide were analyzed
sing ﬂow cytometry. The histogram analysis revealed reductions
n the average cell size of 9.7% and 15.5%, respectively, comparedThe results are expressed as the mean ± SD from 50 parasites. The IC50 and IC90
values represent the concentrations that inhibit cell growth in 50% and 90% after
96 h treatment at 28 ◦C.
with the mean cell size of untreated parasites. Treatment with
50 M actinomycin D (standard drug) reduced cell size by 22.9%.
Ultrastructural changes in epimastigotes treated with guaiano-
lide are illustrated in Fig. 2. Untreated parasites showed organelles
with normal morphology and no plasma alterations (Fig. 2E). Epi-
mastigote forms treated with guaianolide (IC50 and IC90) for 96 h
showed membranes that enveloped reservosomes and the nucleus
and the formation of myelin-like ﬁgures (Fig. 2F–I).
Based on the morphological and ultrastructural data, treated
parasites were or were not incubated with ﬂuorescent markers to
evaluate alterations using ﬂow cytometry. The mitochondrial func-
tion of the parasites was investigated using the ﬂuorescent probe
Rh123, which is collected in energized and respiring mitochondria.
Guaianolide dose-dependently decreased the percentage of Rh123
ﬂuorescence in the upper-right quadrant from 97% in untreated
cells (Fig. 3A) to 76.6% and 47.8%, indicating a decrease in the
m in epimastigotes treated with 18.1 and 44.1 M,  respectively
(Fig. 3C and D). Treatment with the standard drug CCCP at 100 M
reduced ﬂuorescence to 0.3% (Fig. 3B). Epimastigotes treated with
guaianolide (IC50 and IC90) and labeled with PI showed no sig-
niﬁcant alterations in the permeability of the plasma membrane.
The gated percentages (upper-left quadrant) of PI-stained para-
sites after treatment were 3.86% and 12.36%, respectively, very
close to the value obtained with untreated cells. Treatment with
40 M digitonin increased the number of parasites marked with PI
by 68.5% (data not shown).
The activity of guaianolide in trypomastigotes, representing the
main infective stage of T. cruzi, also presented a dose-dependent
effect, in which all concentrations tested showed signiﬁcant activ-
ity compared with controls (p < 0.05). After 24 h of treatment, we
observed a decrease in viability, with EC50 and EC90 values of
5.7 ± 0.7 M and 44.9 ± 2.0 M,  respectively (Fig. 4A). The EC50 of
the reference drug benznidazole was 3.4 ± 0.9 M.  No signiﬁcant
differences were found between the activity of benznidazole and
guaianolide against the trypomastigote form.
Morphological changes induced by guaianolide in trypomasti-
gotes are illustrated in Fig. 4C and D. Trypomastigotes treated with
5.7 and 44.9 M showed changes in body shape, with rounding
and shortening of the parasite and apparent leakage of cytoplasmic
contents, compared with untreated cells (Fig. 4B).
Because of the trypanocidal activity of guaianolide against
epimastigote and trypomastigote forms, the efﬁcacy against intra-
cellular amastigotes in LLCMK2 cells was evaluated using non-toxic
concentrations. When the parasites were treated with guaianolide
for 96 h, we observed a dose-dependent decrease in intracellular
amastigotes. Fig. 5 shows survival indices of 39.5% after treatment
with 70 M guaianolide, 65% after treatment with 60 M, and 80%
after treatment with 50 M.  The IC50 was observed at a concentra-
tion of 66.6 ± 1.3 M guaianolide.
The cytotoxicity assays against mammalian host cells (LLCMK2)
incubated for 96 h showed that guaianolide displayed low toxicity,
exhibiting a CC50 value of 93.5 ± 1.3 M (Table 2). Based on the CC50
J. Cogo et al. / Phytomedicine 20 (2012) 59– 66 63
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pig. 3. Flow cytometry analysis of Rh123-labeled epimastigote of Trypanosoma cruz
CCP  (100 M).  (C) Parasites treated with IC50. (D) Parasites treated with IC90. Th
uadrant.
nd EC50 values, the SI was determined. This compound was at least
6.4-fold more potent against the trypomastigote form compared
ith mammalian cells.
Combinational effects can be demonstrated by calculating the
ICI (Chou 2006). The evaluation of the combinational effect of
ifferent concentrations of both drugs on epimastigotes revealed
ynergistic activity with a FICI of 0.6. As shown previously, the IC50
alues of the reference drug benznidazole and guaianolide for the
pimastigote form were 8.1 and 18.1 M,  respectively. The same
ffect was observed with lower concentrations of both drugs. The
ddition of low concentrations of guaianolide (5.4 M)  resulted in
 reduction of the IC50 value of benznidazole to 3 M.  However,
hen guaianolide was combined with benznidazole against the
rypomastigote form, the IC50 values slightly decreased from 5.7
nd 3.4 M to 2.1 and 1.87 M,  respectively. The FICI was 0.93,
ndicating marginal additive activity. When assessing the effect of
he combination with regard to cytotoxicity in LLCMK2 cells, was
btained a FICI of 1.06, i.e., no increase in the levels of toxicity was
able 2
rypanocidal activity against epimastigote and trypomastigote forms,
ytotoxicity in LLCMK2 cells, and selectivity index of guaianolide (11,13-
ehydrocompressanolide) isolated from Tanacetum parthenium.
Guaianolide (M) SI
Epimastigote IC50 18.1 ± 0.8
Trypomastigote EC50 5.7 ± 0.7 16.4
LLCMK2 cells CC50 93.5 ± 1.3
he results are expressed as the mean ± SD from three independent experiments.
he CC50 value represents the 50% cytotoxic concentration in LLCMK2 cells (96 h at
7 ◦C). The IC50 value represents the concentration that inhibits cell growth in 50%
96 h at 28 ◦C), and the EC50 value represents the concentration that lyses 50% of the
arasites (24 h at 37 ◦C) compared with controls. SI: CC50 LLCMK2/EC50.ed with guaianolide for 96 h at 37 ◦C. (A) Untreated cells. (B) Parasites treated with
bers in bold represent the percentage of collapsed m cells in the upper right
observed. The CC50 values of guaianolide and benznidazole was
93.5 and 1218.2 M,  respectively. The graphical representation of
this interaction is shown in the isobolograms. The isobolograms
formed from the combinations of different concentrations of the
guaianolide and benznidazole (Fig. 6) conﬁrmed the FICI results
(Wagner and Ulrich-Merzenich 2009).
Discussion
The large number of patients who die from Chagas’ disease
and safety and efﬁcacy limitations associated with available treat-
ments emphasize the need for novel trypanocidal drugs (Urbina
2010). Sesquiterpene lactones have been successfully used to
combat a wide variety of parasites that can cause human infec-
tions (Chaturvedi 2011; Julianti et al. 2011). In this context, the
present study sought to investigate the in vitro trypanocidal activ-
ity of 11,13-dehydrocompressanolide isolated from T. parthenium
against T. cruzi.
Our data showed that this compound displayed signiﬁcant activ-
ity against the epimastigote, trypomastigote, and amastigote forms
of T. cruzi and was  effective at low micromolar concentrations that
did not affect mammalian cell viability. The highest activity was
against the trypomastigote form. This result is especially inter-
esting because this form is found in the bloodstream of infected
vertebrates.
Signiﬁcant antiprotozoal activity of sesquiterpene lactones was
reported in previous studies conducted by our group. When tested
against L. amazonensis, guaianolide inﬂuenced the growth of the
amastigote form and showed strong activity against the promastig-
ote form, similar to the results obtained for the epimastigote form
of T. cruzi (Silva et al. 2010). High activity of the hydroalcoholic
extract, fractions, and parthenolide isolated from the aerial parts of
64 J. Cogo et al. / Phytomedicine 20 (2012) 59– 66
Fig. 4. Effect of guaianolide on the viability, morphology and ultrastructure of trypomastigote forms treated for 24 h at 37 ◦C. (A) Viability assay of trypomastigotes treated with
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wuaianolide and benznidazole. The data are expressed as mean ± SD from three ind
f  viable cells compared with untreated parasites. Morphological alterations were
arasites treated with IC50. (E) Parasites treated with IC90, showing changes in body
. parthenium against T. cruzi have been reported, with a progres-
ive increase in the antitrypanosomal effect during the course of the
uriﬁcation process (Izumi et al. 2008). The results obtained with
uaianolide in this study, showed that parthenolide is not solely
esponsible compound present in T. parthenium, for this activity
gainst T. cruzi.
ig. 5. Effect of guaianolide on Trypanosoma cruzi-LLCMK2 cell interaction. (A) LLCMK2 c
he  survival index (SI) was calculated by multiplying the percentage of infected cells by th
quation: (SI control/SI treated cells) × 100. The data are expressed as mean values obtaine
f  each group from control. Light microscopy of Trypanosoma cruzi-infected LLCMK2 cells 
ith  intracellular amastigotes. (C) Cells treated with 60 M presented low infection withent experiments performed in duplicate. The results were analyzed as percentages
rved by SEM. (B) Untreated parasite, showing typical elongated shape. (C and D)
e with apparent leakage of cytoplasmic contents. Scale bars = 1 m.
Several sesquiterpene lactones have been reported to have
trypanocidal activity, including parthenolide, dehydroleucodine,
psilostachyin C, -cyclocostunolide, costunolide, and dehydrocos-
tuslactone (Brengio et al. 2000; Izumi et al. 2008; Sülsen et al.
2010; Julianti et al. 2011). Dehydrocostuslactone and zalunin
D are also guaianolide-type sesquiterpene lactones with potent
ells infected with trypomastigotes and treated with guaianolide for 96 h at 37 ◦C.
e number of amastigotes per cell, and the SI (%) was calculated using the following
d in duplicate from three independent experiments. *p < 0.05, signiﬁcant difference
treated with guaianolide for 96 h at 37 ◦C. (B) Untreated cells showed high infection
 amastigotes. (D) Cells treated with 50 M. 100× magniﬁcation.
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Fig. 6. Isobolograms that illustrate the effect of guaianolide, benznidazole, and their
combination on the epimastigote and trypomastigote forms of Trypanosoma cruzi
and  LLCMK2 cells. (A) Synergistic effect between guaianolide and benznidazole on
epimastigote forms treated for 96 h at 28 ◦C (concave curve). (B) Marginal additive
effect of guaianolide and benznidazole on trypomastigote forms treated for 24 h at
37 ◦C (line over the isobole). (C) Additive effect of guaianolide and benznidazole
o
r
a
o
t
e
e
t
i
t
t
in  LLCMK2 cells incubated for 96 h at 37 ◦C (line over the isobole). The dashed line
epresents the isobole of additivity.
ntitrypanosomal activity against epimastigote and trypomastig-
te forms (Uchiyama et al. 2002).
The trypanocidal activity of this group of compounds relies on
he covalent bond formation of the unsaturated -lactone moi-
ty with nucleophiles, such as the thiol and amino groups of
nzymes, that are essential for the life of the parasite and affects
he trypanothione (1,8-bis-glutathionyl spermidine) redox system,
nactivating the defense system and exposing the parasite to oxida-
ive damage (Uchiyama et al. 2002; Otoguro et al. 2011).
Another explanation for the marked activity displayed against
he multiplicative forms of T. cruzi can be found in the high cytotox-
city against cancer cells, acting mainly on the telomerase (Huangne 20 (2012) 59– 66 65
et al. 2005; Wang et al. 2007; Kanno et al. 2008). Multiple stages
need to divide very quickly. Given the tight connection between
cell division and telomeric extension, the blockade of telomerase
activity by sesquiterpene lactones could provide a way  to control
parasite proliferation and therefore disease formation (Mun˜oz and
Collins 2004; Campelo et al. 2011).
The activity of this class of compounds has usually been associ-
ated with high cytotoxicity. However, some sesquiterpene lactones,
mainly of the guaianolide type, are considerably more toxic to para-
sites than to mammalian cells, as observed in the present study.
The SI for guaianolide was  16.4 for trypomastigotes, showing good
selectivity for this infective form. Recently, the cytotoxicity of this
guaianolide was  also assessed on J774G8 macrophages, with no
toxicity at CC50 > 4000 M (Silva et al. 2010). Cytotoxicity assays
in LLCMK2 cells and J774G8 macrophages showed that partheno-
lide had higher cytotoxicity, with CC50 values of 12.9 and 56.4 M,
respectively (Tiuman et al. 2005; Izumi et al. 2008). These data
indicate that guaianolide presents lower cytotoxicity than the pre-
cursor parthenolide. The lower cytotoxicity of this guaianolide
compared with other guaianolides and sesquiterpene lactones may
be directly related to the alkylation of fewer structural elements
(Scotti et al. 2007; Ghantous et al. 2010; Silva et al. 2010).
The use of drugs derived from natural products for the control of
microorganisms is growing (Wagner and Ulrich-Merzenich 2009).
In the present study, we  found a combinational effect of guaiano-
lide and benznidazole. This combination displayed a synergistic and
nearly additive effect against the epimastigote and trypomastigote
forms, respectively. Recently, a combinational effect of partheno-
lide and benznidazole against T. cruzi was also tested. Strong
synergistic activity against the epimastigote form, an additive affect
against the trypomastigote form, and antagonist effect on cytotox-
icity were observed with this drug combination (Pelizzaro-Rocha
et al. 2010). These results demonstrate that drug combinations can
be an alternative for the treatment of Chagas’ disease because it
allows the use of lower concentrations of benznidazole that may
reduce side effects in patients.
Electron microscopy is a powerful tool for the study of mor-
phological alterations and target organelles in protozoa treated
with compounds from natural products. The effect of guaiano-
lide on the epimastigote and trypomastigote forms should be
determined to evaluate the possible therapeutic use of these com-
pounds against Chagas’ disease. Despite the large number of reports
that have shown the trypanocidal activity of sesquiterpene lac-
tones, few studies have found changes in the parasite caused by
these compounds. In the present study, we  found that guaianolide
caused different morphological alterations in the epimastigote and
trypomastigote forms. Trypomastigotes treated with guaianolide
showed changes in body shape, similar to the effect of partheno-
lide, such as rounding and shortening of the parasite with apparent
leakage of cytoplasmic contents (Pelizzaro-Rocha et al. 2010). The
promastigotes form of L. amazonensis treated with guaianolide pre-
sented different morphological alterations in size and shape (i.e.,
rounded and smaller), and structural alterations, such as the num-
ber of ﬂagellum (Silva et al. 2010). The changes in the structure
and shape of the plasma membrane may  be caused by an action of
sesquiterpene lactones on submembrane microtubules, stimulat-
ing tubulin polymerization (Bocca et al. 2004; Miglietta et al. 2004;
Pelizzaro-Rocha et al. 2010).
An increase in cell length was  observed in the epimastigote
form, followed by a decrease in cell body width. The most signif-
icant change was the increase in ﬂagellum length. This is the ﬁrst
time that such an elongation has been observed in parasites treated
with natural products. The mean ﬂagellar length of the population
is modulated by variations in the concentrations of substances in
the culture medium. Glucose depletion may  signal an increase in
the gene expression of the ﬂagellar components required for the
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onstruction of a longer ﬂagellum (Tyler and Engman 2000). There-
ore, we suggest that guaianolide may  interfere with the absorption
f glucose from the medium, leading to an increase in the ﬂagellum.
The slight changes in mitochondria observed by TEM and ﬂow
ytometry in the epimastigote forms treated with guaianolide
howed that this organelle is not the main target of this compound.
his result differs from other studies of sesquiterpene lactones, in
hich mitochondrial swelling was found (Izumi et al. 2008; Sülsen
t al. 2010). Transmission electron microscopy also revealed the
resence of myelin-like ﬁgures and formation of membranes that
nveloped reservosomes and the nucleus in epimastigote forms
reated with guaianolide. Similar alterations were found in the epi-
astigote form treated with parthenolide (Izumi et al. 2008).
In conclusion, guaianolide exerted actions on trypanosomatids
t low concentrations, with low cytotoxicity in mammalian cells.
hese results suggest that this compound can recognize different
argets in parasites and act through multiple mechanisms. Further
nvestigations are needed to evaluate the underlying mechanism
f action of this compound against parasites.
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